Although this agent is an anti-arrhythmic drug with Na+ channel blocking properties, in mouse models and patients with CPVT it has been shown that it also inhibits RyR2 [117,118]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.